Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

LASER : Treatment of Locally Advanced non-small cell lung carcinoma with Stereotactic ablativE Radiotherapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

OnePhase One

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Radiotherapy | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase I trial will evaluate whether stereotactic ablative radiotherapy (SABR) is a safe and effective treatment option for patients with non-small cell lung cancer (NSCLC) whose cancer is large and/or has spread to the nearby lymph nodes.
 

This trial is treating patients with non-small cell lung cancer.

This is a radiotherapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Treatment of Locally Advanced non-small cell lung carcinoma with Stereotactic ablativE Radiotherapy

Other Non-Commercial Sponsor

Alfred Health

Summary

Stereotactic ablative radiotherapy (SABR) is a specialised form of radiotherapy whereby large doses of radiation are given in fewer treatments. Patients participating in this trial will attend between 6-12 SABR sessions across 2-3 weeks, and will then be followed up regularly post radiotherapy, in order to evaluate treatment safety, quality of life, tumour response and survival.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, William Buckland Radiotherapy Centre
Prahran
Ms Robin Smith
r.smith@alfred.org.au
03 9076 2360

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next